** Cancer therapy developer Zymeworks' ZYME.O shares up as much as 10.6% to $13.91
** Brokerage J.P.Morgan upgrades company's shares to "overweight" from "neutral", raises PT by $6 to $18
** Recent R&D day event has brokerage more confident in company's oncology and autoimmune diseases pipeline, with two distinct TCE, ADC cancer therapies progressing in the clinics - JPM
** Company's cancer drug Zani provides "solid support" to stock valuation - brokerage
** JPM believes 2025 is the year to pay attention and could begin to see one or more of company's "5x5" pipeline plan succeeding in clinics
** Zymeworks' internal portfolio is largely underappreciated at this level as it begins to take shape as a true "multiple shots on goal" story with attractive upside potential - brokerage
** Brokerage Jefferies also raises PT on company's shares by $2 to $24
** 6 of 8 brokerages rate the stock "buy" or higher, and 2 "hold"; median PT $18.75 - LSEG
** Including session moves, stock up 32% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。